Companies Repare Therapeutics Inc.
Repare Therapeutics (RPTX): executive pay, fiscal 2024
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Repare Therapeutics Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers22nd pct.Of 18 peer CEOs
CEO pay, last three years
- $4,991,804FY2023
- $2,368,837FY2024
CEO total pay was $2,368,837 in fiscal 2024, down from $4,991,804 in fiscal 2023.
FY2024: salary $630,500 · bonus $0 · stock awards $278,000 · option awards $1,203,960
Executives and directors
Lloyd Segal · CEOMaria Koehler · ExecutiveMichael Zinda · EVPAnn D. Rhoads · Independent DirectorBriggs Morrison, M.D · Former director (through FY2024)Carol A. Schafer · Independent DirectorDavid Bonita, M.D · Independent DirectorSamarth Kulkarni, Ph.D · Independent DirectorSteve Forte · DirectorSteven Stein, M.D · Independent DirectorSusan M. Molineaux, Ph.D · Independent DirectorThomas Civik · Chair of the BoardTodd Foley · Former director (through FY2024)
Frequently asked questions
Who was the highest-paid executive at Repare Therapeutics Inc. in fiscal 2024?
As disclosed, Lloyd Segal (Former President and Chief Executive Officer) was the highest-paid executive at Repare Therapeutics Inc. in fiscal 2024, with total compensation of $2,368,837.
How does Repare Therapeutics Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Lloyd Segal's total compensation ranked at the 22nd percentile of Repare Therapeutics Inc.'s disclosed peer group.
How did shareholders vote on Repare Therapeutics Inc.'s executive compensation?
As disclosed, 94.06% of shareholders supported Repare Therapeutics Inc.'s executive compensation in the latest say-on-pay vote.
How much does Repare Therapeutics Inc. spend in total on board compensation for fiscal 2024?
As disclosed, Repare Therapeutics Inc. reported total board compensation of $406,891 for fiscal 2024.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Lloyd Segal | $630,500 | $0 | $278,000 | $1,203,960 | $242,743 | $0 | $13,634 | $2,368,837 |
| Former President and Chief Executive Officer | ||||||||
| Maria Koehler | 505,000 | 28,750 | 97,300 | 431,800 | 156,550 | 0 | 10,808 | 1,230,208 |
| Former Executive Vice President, Chief Medical Officer | ||||||||
| Michael Zinda | 474,500 | 28,750 | 97,300 | 431,800 | 147,095 | 0 | 10,808 | 1,190,253 |
| Executive Vice President, Chief Scientific Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Lloyd Segal | $2,368,837 | $4,991,804 | — | ↓ −2,622,967 |
| Maria Koehler | 1,230,208 | 2,090,272 | — | ↓ −860,064 |
| Michael Zinda | 1,190,253 | 1,829,749 | — | ↓ −639,496 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our compensation programs are designed to attract and retain qualified and talented executives, motivate such executives to achieve business goals and reward them for short- and long-term performance with a simple and clear compensation structure. We intend for total compensation to be competitive in the biopharmaceutical marketplace to help achieve short- and long-term financial and operational goals.
| CEO STI target (% of salary) | 55% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2024
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Lloyd Segal | Option | 5,208 | 36.91 | — |
| Maria Koehler | Option | 5,208 | 36.91 | — |
| Michael Zinda | Option | 5,208 | 36.91 | — |
| Maria Koehler | RSU | 14,000 | — | 18,340 |
| Michael Zinda | RSU | 14,000 | — | 18,340 |
| Michael Zinda | RSU | 16,367 | — | 21,441 |
| Maria Koehler | RSU | 17,633 | — | 23,099 |
| Maria Koehler | Option | 31,146 | 15.63 | — |
| Michael Zinda | Option | 31,146 | 15.63 | — |
| Lloyd Segal | RSU | 40,000 | — | 52,400 |
| Michael Zinda | Option | 50,573 | 12.42 | — |
| Lloyd Segal | RSU | 52,367 | — | 68,601 |
| Maria Koehler | Option | 62,109 | 12.42 | — |
| Lloyd Segal | Option | 81,250 | 15.63 | — |
| Maria Koehler | Option | 85,000 | 6.95 | — |
| Michael Zinda | Option | 85,000 | 6.95 | — |
| Lloyd Segal | Option | 179,271 | 12.42 | — |
| Lloyd Segal | Option | 237,000 | 6.95 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Steven Stein, M.DIndependent | $25,431 | $0 | $146,880 | — | $0 | $172,311 |
| Thomas CivikIndependent · Board Chair · Audit · Nominating and Corporate Governance | 75,771 | 0 | 72,352 | — | 1,078 | 149,201 |
| Ann D. RhoadsIndependent · Audit (Chair) · Nominating and Corporate Governance | 56,708 | 0 | 72,352 | — | 1,078 | 130,138 |
| Carol A. SchaferIndependent · Audit · Nominating and Corporate Governance (Chair) | 53,208 | 0 | 72,352 | — | 3,245 | 128,806 |
| Susan M. Molineaux, Ph.DIndependent · Science and Technology | 49,417 | 0 | 72,352 | — | 1,078 | 122,847 |
| David Bonita, M.DIndependent · Compensation · Science and Technology | 46,708 | 0 | 72,352 | — | 0 | 119,060 |
| Samarth Kulkarni, Ph.DIndependent · Compensation | 45,000 | 0 | 72,352 | — | 1,078 | 118,430 |
| Briggs Morrison, M.DIndependent · Departed during FY | 26,534 | 0 | 72,352 | — | 0 | 98,886 |
| Todd FoleyIndependent · Departed during FY | 19,479 | 0 | 0 | — | 1,078 | 20,557 |
| Steve ForteEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 8,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $398,256 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $8,635 |
| Total cost of the board | $406,891 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Repare Therapeutics as a peer
Companies that benchmark against RPTX
2 companies name RPTX as a compensation peer
- AGENUS INCAGENFY2025
- Tango Therapeutics, Inc.TNGXFY2025
Each company listed discloses RPTX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named RPTX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2024
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
REPL Replimune GroupBCYC Bicycle TherapeuticsALXO ALX OncologyMRSN Mersana TherapeuticsAURA Aura BiosciencesPMVP PMV PharmaceuticalsRAPT RAPT TherapeuticsFHTX Foghorn TherapeuticsIDYA IDEAYA BiosciencesSTOK Stoke TherapeuticsINBX InhibrxITOS Iteos TherapeuticsTNGX Tango TherapeuticsKROS Keros TherapeuticsYMAB Y-mAbs TherapeuticsZNTL Zentalis PharmaceuticalsGLUE Monte Rosa TherapeuticsPSTX Poseida Therapeutics
Peer reciprocity
The companies Repare Therapeutics Inc. names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Stoke Therapeutics | 2025 | Ian Smith | $170,625 | $11,590,000 | $14,035,067 | $0 | $27,031,655 |
| 2 | Ideaya Biosciences | 2025 | Yujiro Hata | 700,000 | 0 | 8,418,840 | 378,000 | 9,512,640 |
| 3 | Rapt Therapeutics | 2024 | Brian Wong | 630,000 | 0 | 5,927,297 | 416,000 | 6,979,539 |
| 4 | Bicycle Therapeutics | 2025 | Kevin Lee | 862,339 | 1,724,800 | 2,961,297 | 543,642 | 6,341,473 |
| 5 | Iteos Therapeutics | 2024 | Michel Detheux | 628,684 | 0 | 4,965,264 | 421,014 | 6,085,657 |
| 6 | Replimune Group | 2026 | Sushil Patel | 700,000 | 3,376,003 | 1,448,325 | 315,000 | 5,845,982 |
| 7 | Monte Rosa Therapeutics | 2025 | Markus Warmuth | 650,000 | 910,080 | 3,043,648 | 429,000 | 5,032,728 |
| 8 | Y-mAbs Therapeutics | 2024 | Michael Rossi | 705,600 | 1,170,732 | 2,288,662 | 392,596 | 4,557,590 |
| 9 | Aura Biosciences | 2025 | Elisabet de los Pinos | 645,483 | 1,492,378 | 1,513,293 | 284,013 | 3,956,167 |
| 10 | Poseida Therapeutics | 2023 | Mark Gergen | 611,667 | 1,442,285 | 1,413,936 | 336,420 | 3,818,018 |
| 11 | Inhibrx | 2025 | Mark Lappe | 695,250 | 0 | 0 | 479,723 | 2,892,473 |
| 12 | Tango Therapeutics | 2025 | Barbara Weber | 697,950 | 308,096 | 1,275,328 | 524,250 | 2,823,992 |
| 13 | Keros Therapeutics | 2025 | Jasbir Seehra | 700,000 | 1,426,280 | 0 | 398,125 | 2,540,204 |
| 14 | ALX Oncology | 2025 | Jason Lettmann | 724,500 | 0 | 1,447,488 | 298,856 | 2,470,844 |
| 15 | Repare Therapeutics Inc. | 2024 | Lloyd Segal | 630,500 | 278,000 | 1,203,960 | 242,743 | 2,368,837 |
| 16 | Foghorn Therapeutics | 2025 | Adrian Gottschalk | 638,000 | 0 | 1,334,037 | 385,990 | 2,361,027 |
| 17 | PMV Pharmaceuticals | 2025 | David Mack | 628,461 | 0 | 752,320 | 284,410 | 1,665,191 |
| 18 | Mersana Therapeutics | 2024 | Michael Huber | 632,500 | 133,635 | 518,044 | 322,575 | 1,613,754 |
| 19 | Zentalis Pharmaceuticals | 2025 | Julie Eastland | 700,000 | 99,772 | 56,975 | 441,000 | 1,300,731 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Repare Therapeutics Inc. | 70% | not disclosed | not disclosed | Aon |
| ALX Oncology | not disclosed | not disclosed | not disclosed | Compensia |
| Aura Biosciences | not disclosed | not disclosed | not disclosed | Pay Governance |
| Bicycle Therapeutics | 97% | not disclosed | not disclosed | not disclosed |
| Foghorn Therapeutics | not disclosed | Options 100 | not disclosed | Pay Governance, LLC |
| Ideaya Biosciences | 90% | Options 100 | not disclosed | Aon (Aon plc, Talent Solutions practice) |
| Inhibrx | not disclosed | Option 100 | not disclosed | not disclosed |
| Iteos Therapeutics | not disclosed | not disclosed | not disclosed | Radford |
| Keros Therapeutics | 87.5% | RSU 50 · PSU 50 | No | Aon (Human Capital Solutions practice) |
| Mersana Therapeutics | not disclosed | Option 75 · RSU 25 | not disclosed | Pearl Meyer & Partners, LLC |
| Monte Rosa Therapeutics | not disclosed | not disclosed | not disclosed | Radford, an Aon Hewitt Company |
| PMV Pharmaceuticals | not disclosed | Option 100 | not disclosed | Pearl Meyer & Partners, LLC |
| Poseida Therapeutics | not disclosed | not disclosed | not disclosed | Aon Consulting, Inc. |
| Rapt Therapeutics | 120% | Option 100 | not disclosed | Aon plc/Radford |
| Replimune Group | not disclosed | not disclosed | No | Pearl Meyer |
| Stoke Therapeutics | not disclosed | not disclosed | not disclosed | Aon |
| Tango Therapeutics | not disclosed | not disclosed | not disclosed | Pearl Meyer |
| Y-mAbs Therapeutics | 85.6% | not disclosed | No | Aon |
| Zentalis Pharmaceuticals | 105% | not disclosed | not disclosed | Anderson Pay Advisors LLC / Pay Governance LLC |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-06-17 | 27,990,552 | 1,766,930 | — | 94.06% | Passed |
| 2024 | 2024-06-17 | 32,257,365 | 25,262 | — | 99.92% | Passed |
| 2023 | 2023-06-08 | 36,408,559 | 28,413 | — | 99.92% | Passed |
| 2022 | 2022-05-13 | 37,014,595 | 125,277 | 1,459 | 99.66% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2025 | 2025-06-17 | 94.06%a |
| 2024 | 2024-06-17 | 99.92%b |
| 2023 | 2023-06-08 | 99.92%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Alves Sandra Isabelle Barros | SVP, Finance and CAO | 2026-01-28 | D | 26,000 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Alves Sandra Isabelle Barros | SVP, Finance and CAO | 2026-01-28 | D | 31,622 | — | — | Common | Form 4 ↗ |
| Steve Forte | EVP, Chief Financial Officer | 2026-01-28 | D | 500,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steve Forte | EVP, Chief Financial Officer | 2026-01-28 | D | 200,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steve Forte | EVP, Chief Financial Officer | 2026-01-28 | D | 56,786 | — | — | Common | Form 4 ↗ |
| BVF PARTNERS L P/IL | Greater-than-10% holder | 2026-01-28 | D | 5,309,432 | — | — | Common, indirect | Form 4 ↗ |
| Alves Sandra Isabelle Barros | SVP, Finance and CAO | 2026-01-28 | D | 24,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ann D. Rhoads | Director | 2026-01-28 | D | 4,000 | — | — | Common | Form 4 ↗ |
| Carol A. Schafer | Director | 2026-01-28 | D | 37,941 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Carol A. Schafer | Director | 2026-01-28 | D | 8,000 | — | — | Common | Form 4 ↗ |
| BVF PARTNERS L P/IL | Greater-than-10% holder | 2026-01-28 | D | 4,308,573 | — | — | Common, indirect | Form 4 ↗ |
| Steve Forte | EVP, Chief Financial Officer | 2026-01-28 | D | 85,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas Civik | Director | 2026-01-28 | D | 7,500 | — | — | Common | Form 4 ↗ |
| BVF PARTNERS L P/IL | Greater-than-10% holder | 2026-01-28 | D | 548,938 | — | — | Common, indirect | Form 4 ↗ |
| Steve Forte | EVP, Chief Financial Officer | 2026-01-28 | D | 325,800 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (54 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Lloyd Segal. DEF 14A, filed 2025-04-29. Section “Executive Compensation”. As printed: 2,368,837. View filing ↗
- Section 01, Maria Koehler. DEF 14A, filed 2025-04-29. Section “Executive Compensation”. As printed: 1,230,208. View filing ↗
- Section 01, Michael Zinda. DEF 14A, filed 2025-04-29. Section “Executive Compensation”. As printed: 1,190,253. View filing ↗
- Section 08, Steven Stein, M.D. DEF 14A, filed 2025-04-29. Section “Director Compensation”. As printed: 172,311. View filing ↗
- Section 08, Thomas Civik. DEF 14A, filed 2025-04-29. Section “Director Compensation”. As printed: 149,201. View filing ↗
- Section 08, Ann D. Rhoads. DEF 14A, filed 2025-04-29. Section “Director Compensation”. As printed: 130,138. View filing ↗
- Section 08, Carol A. Schafer. DEF 14A, filed 2025-04-29. Section “Director Compensation”. As printed: 128,806. View filing ↗
- Section 08, Susan M. Molineaux, Ph.D. DEF 14A, filed 2025-04-29. Section “Director Compensation”. As printed: 122,847. View filing ↗
- Section 08, David Bonita, M.D. DEF 14A, filed 2025-04-29. Section “Director Compensation”. As printed: 119,060. View filing ↗
- Section 08, Samarth Kulkarni, Ph.D. DEF 14A, filed 2025-04-29. Section “Director Compensation”. As printed: 118,430. View filing ↗
- Section 08, Briggs Morrison, M.D. DEF 14A, filed 2025-04-29. Section “Director Compensation”. As printed: 98,886. View filing ↗
- Section 08, Todd Foley. DEF 14A, filed 2025-04-29. Section “Director Compensation”. As printed: 20,557. View filing ↗
- Section 08, Steve Forte. DEF 14A, filed 2025-04-29. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Alves Sandra Isabelle Barros 2026-01-28. Form 4, filed 2026-01-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alves Sandra Isabelle Barros 2026-01-28. Form 4, filed 2026-01-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steve Forte 2026-01-28. Form 4, filed 2026-01-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steve Forte 2026-01-28. Form 4, filed 2026-01-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steve Forte 2026-01-28. Form 4, filed 2026-01-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BVF PARTNERS L P/IL 2026-01-28. Form 4, filed 2026-01-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alves Sandra Isabelle Barros 2026-01-28. Form 4, filed 2026-01-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ann D. Rhoads 2026-01-28. Form 4, filed 2026-01-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Carol A. Schafer 2026-01-28. Form 4, filed 2026-01-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Carol A. Schafer 2026-01-28. Form 4, filed 2026-01-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BVF PARTNERS L P/IL 2026-01-28. Form 4, filed 2026-01-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steve Forte 2026-01-28. Form 4, filed 2026-01-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Civik 2026-01-28. Form 4, filed 2026-01-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BVF PARTNERS L P/IL 2026-01-28. Form 4, filed 2026-01-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steve Forte 2026-01-28. Form 4, filed 2026-01-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-17. Item 5.07 · say-on-pay result. As reported: 94.06% (votes for as printed: 27,990,552). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-17. Item 5.07 · say-on-pay result. As reported: 99.92% (votes for as printed: 32,257,365). View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-06-09. Item 5.07 · say-on-pay result. As reported: 99.92% (votes for as printed: 36,408,559). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 398,256 + equity 0 + all other 8,635 = 406,891, summed across the director compensation table rows.
- Stoke Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Stoke Therapeutics's own proxy. As printed: 27,031,655. View filing ↗
- Ideaya Biosciences, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Ideaya Biosciences's own proxy. As printed: 9,512,640. View filing ↗
- Rapt Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-14. CEO total compensation as printed in Rapt Therapeutics's own proxy. As printed: 6,979,539. View filing ↗
- Bicycle Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Bicycle Therapeutics's own proxy. As printed: 6,341,473. View filing ↗
- Iteos Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in Iteos Therapeutics's own proxy. As printed: 6,085,657. View filing ↗
- Replimune Group, Section 10b CEO total. DEF 14A, filed 2026-07-29. CEO total compensation as printed in Replimune Group's own proxy. As printed: 5,845,982. View filing ↗
- Monte Rosa Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Monte Rosa Therapeutics's own proxy. As printed: 5,032,728. View filing ↗
- Y-mAbs Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-05-30. CEO total compensation as printed in Y-mAbs Therapeutics's own proxy. As printed: 4,557,590. View filing ↗
- Aura Biosciences, Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in Aura Biosciences's own proxy. As printed: 3,956,167. View filing ↗
- Poseida Therapeutics, Section 10b CEO total. DEF 14A, filed 2024-04-25. CEO total compensation as printed in Poseida Therapeutics's own proxy. As printed: 3,818,018. View filing ↗
- Inhibrx, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Inhibrx's own proxy. As printed: 2,892,473. View filing ↗
- Tango Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Tango Therapeutics's own proxy. As printed: 2,823,992. View filing ↗
- Keros Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Keros Therapeutics's own proxy. As printed: 2,540,204. View filing ↗
- ALX Oncology, Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in ALX Oncology's own proxy. As printed: 2,470,844. View filing ↗
- Repare Therapeutics Inc. (subject), Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Repare Therapeutics Inc.'s own proxy. As printed: 2,368,837. View filing ↗
- Foghorn Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Foghorn Therapeutics's own proxy. As printed: 2,361,027. View filing ↗
- PMV Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in PMV Pharmaceuticals's own proxy. As printed: 1,665,191. View filing ↗
- Mersana Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Mersana Therapeutics's own proxy. As printed: 1,613,754. View filing ↗
- Zentalis Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Zentalis Pharmaceuticals's own proxy. As printed: 1,300,731. View filing ↗
- Section 10a, PMV Pharmaceuticals reciprocity. DEF 14A. PMV Pharmaceuticals names Repare Therapeutics Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Tango Therapeutics reciprocity. DEF 14A. Tango Therapeutics names Repare Therapeutics Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗